Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1977 1
1985 1
1986 2
1991 1
1993 2
1996 1
1998 4
1999 2
2000 1
2001 1
2003 1
2004 1
2005 1
2006 1
2008 1
2009 1
2011 3
2012 2
2013 3
2014 4
2015 7
2016 3
2017 2
2018 7
2019 6
2020 14
2021 5
2022 7
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Citations

3 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nøhr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilvásy-Szabó A, Willenbrock H, Secher A, Knudsen LB, Hogendorf WFJ. Gabery S, et al. JCI Insight. 2020 Mar 26;5(6):e133429. doi: 10.1172/jci.insight.133429. JCI Insight. 2020. PMID: 32213703 Free PMC article.
Semaglutide directly accessed the brainstem, septal nucleus, and hypothalamus but did not cross the blood-brain barrier; it interacted with the brain through the circumventricular organs and several select sites adjacent to the ventricles. ...Transcriptomic analysis …
Semaglutide directly accessed the brainstem, septal nucleus, and hypothalamus but did not cross the blood-brain barrier; it interacte …
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho TH, Fazekas F, Fiehler J, Ford I, Galinovic I, Gellissen S, Golsari A, Gregori J, Günther M, Guibernau J, Häusler KG, Hennerici M, Kemmling A, Marstrand J, Modrau B, Neeb L, Perez de la Ossa N, Puig J, Ringleb P, Roy P, Scheel E, Schonewille W, Serena J, Sunaert S, Villringer K, Wouters A, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C; WAKE-UP Investigators. Thomalla G, et al. N Engl J Med. 2018 Aug 16;379(7):611-622. doi: 10.1056/NEJMoa1804355. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766770 Free article. Clinical Trial.
Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
Thomalla G, Boutitie F, Ma H, Koga M, Ringleb P, Schwamm LH, Wu O, Bendszus M, Bladin CF, Campbell BCV, Cheng B, Churilov L, Ebinger M, Endres M, Fiebach JB, Fukuda-Doi M, Inoue M, Kleinig TJ, Latour LL, Lemmens R, Levi CR, Leys D, Miwa K, Molina CA, Muir KW, Nighoghossian N, Parsons MW, Pedraza S, Schellinger PD, Schwab S, Simonsen CZ, Song SS, Thijs V, Toni D, Hsu CY, Wahlgren N, Yamamoto H, Yassi N, Yoshimura S, Warach S, Hacke W, Toyoda K, Donnan GA, Davis SM, Gerloff C; Evaluation of unknown Onset Stroke thrombolysis trials (EOS) investigators. Thomalla G, et al. Lancet. 2020 Nov 14;396(10262):1574-1584. doi: 10.1016/S0140-6736(20)32163-2. Epub 2020 Nov 8. Lancet. 2020. PMID: 33176180 Free PMC article.
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjöstrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L; Gore REDUCE Clinical Study Investigators. Søndergaard L, et al. N Engl J Med. 2017 Sep 14;377(11):1033-1042. doi: 10.1056/NEJMoa1707404. N Engl J Med. 2017. PMID: 28902580 Free article. Clinical Trial.
Imaging of the brain was performed at the baseline screening and at 24 months. The coprimary end points were freedom from clinical evidence of ischemic stroke (reported here as the percentage of patients who had a recurrence of stroke) through at least 24 months after rand …
Imaging of the brain was performed at the baseline screening and at 24 months. The coprimary end points were freedom from clinical ev …
Systemic proteome adaptions to 7-day complete caloric restriction in humans.
Pietzner M, Uluvar B, Kolnes KJ, Jeppesen PB, Frivold SV, Skattebo Ø, Johansen EI, Skålhegg BS, Wojtaszewski JFP, Kolnes AJ, Yeo GSH, O'Rahilly S, Jensen J, Langenberg C. Pietzner M, et al. Nat Metab. 2024 Apr;6(4):764-777. doi: 10.1038/s42255-024-01008-9. Epub 2024 Mar 1. Nat Metab. 2024. PMID: 38429390
The fasting signature is strongly enriched for extracellular matrix proteins from various body sites, demonstrating profound non-metabolic adaptions, including extreme changes in the brain-specific extracellular matrix protein tenascin-R. Using proteogenomic approaches, we …
The fasting signature is strongly enriched for extracellular matrix proteins from various body sites, demonstrating profound non-metabolic a …
Exercise as Gene Therapy: BDNF and DNA Damage Repair.
Schmidt RH, Nickerson JM, Boatright JH. Schmidt RH, et al. Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):309-11. doi: 10.1097/APO.0000000000000226. Asia Pac J Ophthalmol (Phila). 2016. PMID: 27488073 Free PMC article. Review.
DNA damage is a common feature of neurodegenerative illnesses, and the ability to repair DNA strand breaks and lesions is crucial for neuronal survival, reported by Jeppesen et al (Prog Neurobiol. 2011;94:166-200) and Shiwaku et al (Curr Mol Med. 2015;15:119-128). ...Here, …
DNA damage is a common feature of neurodegenerative illnesses, and the ability to repair DNA strand breaks and lesions is crucial for neuron …
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Hokusai-VTE Investigators; Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Hokusai-VTE Investigators, et al. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. N Engl J Med. 2013. PMID: 23991658 Free article. Clinical Trial.
A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the wa …
A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain …
Psychopharmacology in children and adolescents: unmet needs and opportunities.
Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, Banaschewski T, Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Correll CU, Grünblatt E, Hoekstra PJ, James A, Jeppesen P, Nagy P, Pagsberg AK, Parellada M, Persico AM, Roessner V, Santosh P, Simonoff E, Stevanovic D, Stringaris A, Vitiello B, Walitza S, Weizman A, Wong ICK, Zalsman G, Zuddas A, Carucci S, Butlen-Ducuing F, Tome M, Bea M, Getin C, Hovén N, Konradsson-Geuken A, Lamirell D, Olisa N, Nafria Escalera B, Moreno C. Cortese S, et al. Lancet Psychiatry. 2024 Feb;11(2):143-154. doi: 10.1016/S2215-0366(23)00345-0. Epub 2023 Dec 7. Lancet Psychiatry. 2024. PMID: 38071998 Review.
The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications.
Cortese S, McGinn K, Højlund M, Apter A, Arango C, Baeza I, Banaschewski T, Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Grünblatt E, Hoekstra PJ, James A, Jeppesen P, Nagy P, Pagsberg AK, Parellada M, Persico AM, Purper-Ouakil D, Roessner V, Santosh P, Simonoff E, Stevanovic D, Stringaris A, Vitiello B, Walitza S, Weizman A, Wohlfarth T, Wong ICK, Zalsman G, Zuddas A, Moreno C, Solmi M, Correll CU. Cortese S, et al. Neurosci Biobehav Rev. 2023 Jun;149:105149. doi: 10.1016/j.neubiorev.2023.105149. Epub 2023 Mar 29. Neurosci Biobehav Rev. 2023. PMID: 37001575 Free article. Review.
DNA repair deficiency in neurodegeneration.
Jeppesen DK, Bohr VA, Stevnsner T. Jeppesen DK, et al. Prog Neurobiol. 2011 Jul;94(2):166-200. doi: 10.1016/j.pneurobio.2011.04.013. Epub 2011 Apr 30. Prog Neurobiol. 2011. PMID: 21550379 Free PMC article. Review.
87 results